Summary
The product Artvigil 150 mg, manufactured by HAB Pharmaceuticals, underwent testing to verify its active ingredient and potency. Submitted and funded by Modawhale, the sample was analyzed by Janoshik Analytical, a laboratory specializing in pharmaceutical analysis. The testing confirmed the presence of armodafinil at a measured concentration of 165.89 mg per tablet, reflecting a 10.59% variance above the labeled specification of 150 mg.
The testing process began on 31 October 2024, the sample was received on 5 November 2024, and the analysis was completed on 11 November 2024. While the higher-than-labeled concentration is notable, readers should interpret these findings with caution due to the involvement of the reseller in submitting the sample. Independent third-party testing of market-acquired products is recommended to confirm batch consistency.
Detailed Report
Product Overview
- Manufacturer: HAB Pharmaceuticals
- Product Name: Artvigil 150 mg
- Active Ingredient: Armodafinil
- Batch Number: Unknown
- Expiration Date: Not provided
- Delivery Method: Oral tablet
Sample Acquisition and Testing
- Task Number: #52191
- Testing Ordered: 31 October 2024
- Sample Received: 5 November 2024
- Analysis Conducted By: Janoshik Analytical
- Product Submitted By: Modawhale (Reseller)
- Analysis Paid For By: Modawhale
Testing Results
- Specification: 150 mg (as stated on the label)
- Measured Concentration: 165.89 mg
- Accuracy: 110.59% (10.59% above the label claim)
Verification Details
- Verification URL: https://janoshik.com/tests/52191_TE1BAQ2G5VBG
- Originally Published: https://thinksteroids.com/community/posts/3373596/
Evaluation of Reseller-Submitted Testing
The test results indicate a significant 10.59% overdosage of armodafinil, which exceeds the labeled claim. While this suggests strong manufacturing practices by HAB Pharmaceuticals, the sample’s submission and funding by Modawhale raise concerns about selective sample submission. Resellers may prioritize sending batches known to meet or exceed specifications. Cross-referencing with independent, market-acquired samples is essential to ensure consistent product quality and mitigate potential bias.
Conclusion
The analysis shows that Artvigil 150 mg contains 165.89 mg of armodafinil, exceeding its labeled specification by 10.59%. While this overdosage may appeal to some users, it emphasizes the importance of verifying products through independent testing to confirm consistent dosing across all batches. Consumers should remain vigilant when relying on reseller-submitted testing reports.
Disclaimer
This report is published for educational and harm reduction purposes. Reseller-submitted testing may involve inherent biases due to selective sample submissions. The findings pertain solely to the tested batch and may not represent all products under the same name. Readers are encouraged to cross-reference these results with independent third-party testing for additional validation and use this information responsibly.
